TICKERNERD
Menu
ABEOABEOHealthcare · Biotechnology

ABEO Stock Forecast: Abeona Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.96
−2.36% on the day

The 7 Wall Street analysts covering Abeona Therapeutics, Inc. hold a median 12-month price target of $17 — +242.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$290.5M
Ticker Nerd rank
40 / 100
Median analyst target
$17
Analysts covering
7
Revenue$11.4M+2745.0% y/y
Operating income−$13.7M
Net income−$20.2M
Free cash flow−$18.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
−15.2%
YTD
−5.9%
1Y
−10.5%
From 52W high
−33.5%
From 52W low
+18.9%
$4.17
$7.46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABEO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Abeona Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
69
Size
62
Issuance
56
Growth
56
Value
51
Volatility
47
Revisions
36
Accruals
32
Momentum
29

Quality (69): The business earns solid, repeatable profits on what it owns.

Momentum (29): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABEO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABEO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00$30.00Jan 26Apr 26Jul 26Oct 26ABEOHigh $30Median $17Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $14Median $17High $30

The green dot is the last close — the median target sits +242.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Sept 2026Cantor FitzgeraldMaintainsOverweight$28 → $30
17 Sept 2026Roth CapitalInitiatesBuy$17
14 Aug 2026OppenheimerMaintainsOutperform$22 → $21
14 Aug 2026OppenheimerMaintainsOutperform—
28 May 2026HC Wainwright & Co.ReiteratesBuy$20
28 May 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
13 Oct 2025HC Wainwright & Co.ReiteratesBuy—
18 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025OppenheimerMaintainsOutperform—
16 July 2025HC Wainwright & Co.ReiteratesBuy—
14 July 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025OppenheimerAssumesOutperform$19
16 May 2025StifelMaintainsBuy—
30 Apr 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Mar 2025OppenheimerInitiatesOutperform—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABEO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABEO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Abeona Therapeutics, Inc. returned −10.5% against +16.2% for the S&P 500, dividends included.

ABEO vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130140Jan 26Apr 26Jul 26Oct 26ABEOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABEO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Abeona Therapeutics, Inc. (ABEO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.8×

Cheaper than 62% of US stocks

Price / sales
11.2×

Cheaper than 13% of US stocks

Price / book
2.2×

Cheaper than 41% of US stocks

EV / EBITDA
−2.0×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
2745.0%

Higher than 99% of US stocks

Earnings growth (YoY)
2745.0%

Higher than 99% of US stocks

Gross margin
63.3%

Higher than 76% of US stocks

Operating margin
−120.0%

Higher than 13% of US stocks

Net margin
−246.4%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−43.1%

Higher than 23% of US stocks

Return on assets
−24.6%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Abeona Therapeutics, Inc. (ABEO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Abeona Therapeutics, Inc. has a market value of $290.5M and an enterprise value of $163.5M.

  • Revenue in the twelve months to 30 June 2026: $25.5M. The latest quarter grew 2745.0% year on year.

  • Net income over the same four quarters: −$62.9M, a −246.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$81.5M, after $5.1M of capital spending.

  • Shares outstanding: 57.2M.

  • Trailing P/E: 7.8×; forward P/E: −24.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Abeona Therapeutics, Inc. employs 226 people — $113K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ABEO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABEOAbeona Therapeutics, Inc.$290.5M
40
RCKTRocket Pharmaceuticals, Inc.$284.6M
58
LRMRLarimar Therapeutics, Inc.$285.1M
29
FULCFulcrum Therapeutics, Inc.$286.1M
38
EYPTEyePoint, Inc.$286.4M
11
XFORX4 Pharmaceuticals, Inc.$276.6M
58
BBOTBridgebio Oncology Therapeutics, Inc.$274.2M
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Abeona Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABEO news & analysis

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Abeona Therapeutics announced it has granted equity awards to new non-executive employees who recently joined the company. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This is relevant to ABEO watchers because such inducement grants reflect the company's ongoing hiring activity and equity compensation practices under Nasdaq rules.

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

MarketBeat · 22 Sept 2026positive

Abeona Therapeutics highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. The company emphasised launch momentum and revenue growth at the event.

Why it matters — Abeona watchers would care because the company is signalling that ZEVASKYN is gaining traction commercially, reflecting early market adoption of its key therapy.

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum

MarketBeat · 22 Sept 2026neutral

Abeona Therapeutics executives discussed the early commercial rollout of ZEVASKYN, its autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, at the Morgan Stanley Global Healthcare Conference. Management noted the launch requires a longer foundation-building period than conventional drugs due to individualized manufacturing, limited shelf life, and specialized treatment-center requirements.

Why it matters — Abeona watchers would care because management's commentary provides insight into the early-stage commercial trajectory of ZEVASKYN and the operational factors shaping its rollout.

Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week

Benzinga · 18 Sept 2026positive

Abeona Therapeutics had a busy week involving a new treatment center activation, an FDA approval for a drug the company had licensed out — which entitles Abeona to royalties — and multiple fresh analyst ratings.

Why it matters — A BE O watchers would care because the FDA approval of a licensed-away drug triggers royalty income for Abeona, alongside progress from the new treatment center activation.

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewsWire · 18 Sept 2026positive

Abeona Therapeutics congratulated Ultragenyx on the U.S. FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). The company described the approval as a monumental milestone that validates Abeona's foundational R&D and clinical development efforts.

Why it matters — Abeona watchers would note that this approval validates Abeona's foundational research and clinical development work in the MPS IIIA space.

FAQ

Frequently asked questions about ABEO stock

What is the ABEO stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Abeona Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABEO stock a buy right now?

Of the 7 analysts covering Abeona Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abeona Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABEO?

As at 8 Oct 2026, Abeona Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (69 of 100).

Will ABEO stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +242.7% from the last close, and Ticker Nerd's factor model ranks Abeona Therapeutics, Inc. 40 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABEO stock forecast for 2030?

No analyst covering Abeona Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.

How has ABEO stock performed over the past year?

Abeona Therapeutics, Inc. returned -10.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Abeona Therapeutics, Inc. do?

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases.

What is the latest news on ABEO?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Abeona Therapeutics announced it has granted equity awards to new non-executive employees who recently joined the company. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Abeona Therapeutics, Inc.

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases. Its current portfolio centers on ZEVASKYN, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, alongside a pipeline of adeno-associated virus-based programs for ophthalmic and other genetic disorders. The company also develops engineered T-cell and viral vector technologies designed to address high-unmet-need conditions in oncology and rare disease settings. Abeona Therapeutics operates from Cleveland, Ohio, with a fully integrated cGMP manufacturing facility that supports commercial production and clinical development activities. The company serves the biotechnology and advanced therapies market, where it plays a specialized role in translating genetic medicine into targeted treatments for patients with limited therapeutic options.

CEO Dr. Vishwas Seshadri M.B.A., Ph.D. · 226 employees · United States · https://www.abeonatherapeutics.com